June 2019 - Volume 3 - Issue S1 - Contributor Index

PB2230 SYSTEMIC MASTOCYTOSIS WITH ASSOCIATED HEMATOLOGIC NEOPLASM, EVOLVING TO SIMULTANEOUS CD33 POSITIVE MAST CELL LEUKEMIA AND ACUTE MYELOID LEUKEMIA, TREATED WITH GEMTUZUMAB-OZOGAMICIN

López-Pereira, P.; Figuera, Á.; Ormazábal, I.; More

HemaSphere. 3(S1):999-1000, June 2019.

Author:
Aapro, M.
Author:
Ababou, M.
Author:
Abadi, U.

PF325 REAL - LIFE DATA ON ROMIDEPSIN TREATMENT FOR RELAPSED AND REFRACTORY PERIPHERAL AND CUTANEOUS T-CELL LYMPHOMA - A MULTICENTER NATIONAL OBSERVATIONAL STUDY

Shimony, S.; Horowitz, N.; Ribakovsky, E.; More

HemaSphere. 3(S1):115, June 2019.

Author:
Abagiu, A.
Author:
Abáigar, M.

PF533 MUTATIONS ON COHESIN COMPLEX ARE ASSOCIATED TO A POOR PROGNOSIS IN LOW-RISK MYELODYSPLASTIC SYNDROMES PATIENTS

Martín-Izquierdo, M.; López-Cadenas, F.; Sánchez del Real, J.; More

HemaSphere. 3(S1):219-220, June 2019.

PB2080 ROLE OF SOMATIC MUTATIONS IN PATIENTS WITH HIGH-RISK MYELODISPLASTIC SYNDROMES TREATED WITH INTENSIVE CHEMOTHERAPY

Caballero, J. C.; Sánchez, J. M. Hernández; Abáigar, M.; More

HemaSphere. 3(S1):937-938, June 2019.

Author:
Abali, H.

PS1245 NIVOLUMAB FOR RELAPSED OR REFRACTORY HODGKIN LYMPHOMA: LONG TERM RESULTS OF MULTI-CENTER EXPERIENCE IN TURKEY

Ferhanoglu, B.; Ozbalak, M.; Bekoz, H.; More

HemaSphere. 3(S1):567-568, June 2019.

Author:
Abarrategi, A.
Author:
Abasov, R.
Author:
Abate, A.
Author:
Abbà, C.
Author:
abbadi, M. R.
Author:
abbadi, M.R.
Author:
Abbas, H.

PF205 RNA BASED IMMUNE SIGNATURES MAY PREDICT RESPONSES TO PD-1 INHIBITION AND AZACITIDINE TREATMENT IN ACUTE MYELOID LEUKEMIA (AML): A SUBSET ANALYSIS OF A PHASE 2 STUDY

Abbas, H.; Alfayez, M.; Wang, F.; More

HemaSphere. 3(S1):54-55, June 2019.

S1615 SAFETY, EFFICACY, AND BIOMARKERS OF RESPONSE TO AZACITIDINE (AZA) WITH NIVOLUMAB (NIVO) AND IPILIMUMAB (IPI), AND AZA WITH NIVO IN R/R ACUTE MYELOID LEUKEMIA: A NON-RANDOMIZED, PHASE 2 STUDY.

Daver, N.; Alfayez, M.; Garcia-Manero, G.; More

HemaSphere. 3(S1):745, June 2019.

Author:
Abbaszadeh, Z.

S1635 ACADEMIC, PHASE1 TRIAL ON T CELLS EXPRESSING BOTH CD19 CHIMERIC ANTIGEN RECEPTOR AND INDUCIBLE CASPASE 9 SAFETY SWITCH FOR TREATMENT OF CHILDHOOD ACUTE LYMPHOBLASTIC LEUKAEMIA AND NON-HODGKIN LYMPHOMA

Del Bufalo, F.; Merli, P.; Vinti, L.; More

HemaSphere. 3(S1):755, June 2019.

Author:
Abbati, G.
Author:
Abbenante, M.

PS997 A NEW BIOMARKER OF RESPONSE TO 5-AZACITIDINE THERAPY IN MDS AND AML PATIENTS: SIRPB1

Cerchione, C.; Guadagnuolo, V.; Papayannidis, C.; More

HemaSphere. 3(S1):448-449, June 2019.

PB1726 DOUBLE FLUDARABINE-BASED INDUCTION AND INFECTIVE RISK: THE BOLOGNA EXPERIENCE.

Sartor, C.; De Polo, S.; Lewis, R.E.; More

HemaSphere. 3(S1):794, June 2019.

PB2324 LONG TERM OUTCOME OF AUTOLOGOUS STEM CELL TRANSPLANTATION IN ADULT ACUTE MYELOID LEUKEMIA PATIENTS: THE ROLE OF MINIMAL RESIDUAL DISEASE

Paolini, S.; Romani, L.; Ottaviani, E.; More

HemaSphere. 3(S1):1036, June 2019.

Author:
Abboud, C.

PS1176 PRIMARY RESULTS OF THE PHASE 4 BYOND STUDY OF BOSUTINIB FOR PRETREATED CHRONIC PHASE CHRONIC MYELOID LEUKEMIA

Hochhaus, A.; Gambacorti-Passerini, C.; Abboud, C.; More

HemaSphere. 3(S1):535, June 2019.

Author:
Abboud, M.

PB2300 IMPACT OF SICKLE CELL DISEASE FROM PATIENTS’ AND PHYSICIANS’ PERSPECTIVES: RESULTS FROM THE INTERNATIONAL SICKLE CELL WORLD ASSESSMENT SURVEY (SWAY)

Osunkwo, I.; Abboud, M.; Andemariam, B.; More

HemaSphere. 3(S1):1026-1027, June 2019.

Author:
Abboud, M.R.

S147 RESULTS FROM THE RANDOMIZED PLACEBO-CONTROLLED PHASE 3 HOPE TRIAL OF VOXELOTOR IN ADULTS AND ADOLESCENTS WITH SICKLE CELL DISEASE

Vichinsky, E.; Hoppe, C.C.; Ataga, K.I.; More

HemaSphere. 3(S1):25-26, June 2019.

Author:
Abbruzzese, E.

S123 SETD2 LOSS OF FUNCTION IS A RECURRENT EVENT IN ADVANCED-PHASE CHRONIC MYELOID LEUKEMIA INDUCED BY POST-TRANSLATIONAL MECHANISMS THAT CAN BE THERAPEUTICALLY TARGETED

Mancini, M.; De Santis, S.; Monaldi, C.; More

HemaSphere. 3(S1):13-14, June 2019.

Author:
Abby, E.
Author:
Abdallah, A.
Author:
Abdel Azim, S.
Author:
Abdelfatah, R.
Author:
Abdelhadi, T.

PB1893 NON-INTERVENTIONAL RETROSPECTIVE MULTICENTER STUDY EVALUATING REAL WORD IDELALISIB USE IN CLL AND INHL PATIENTS ENROLLED IN THE FRENCH EARLY ACCESS PROGRAM (EAP)

Ysebaert, L.; Feugier, P.; Salles, G.; More

HemaSphere. 3(S1):862-863, June 2019.

Author:
Abdelhafeez, A.

PB2424 AUGMENTED AND SYNERGISTIC EFFECT OF FACTOR V LEIDEN (FVL) AND MTHFR GENES POLYMORPHISMS AND PLATELET ACTIVITY AND REACTIVITY AS RISK FACTORS FOR ISCHEMIC CEREBROVASCULAR STROKE (IS)

Abdelhamid, A.E.S.; Nashaat, H.-A. Hassan; Ahmed, A. Sayed; More

HemaSphere. 3(S1):1075, June 2019.

PB2424 AUGMENTED AND SYNERGISTIC EFFECT OF FACTOR V LEIDEN (FVL) AND MTHFR GENES POLYMORPHISMS AND PLATELET ACTIVITY AND REACTIVITY AS RISK FACTORS FOR ISCHEMIC CEREBROVASCULAR STROKE (IS)

Abdelhamid, A.E.S.; Nashaat, H.-A. Hassan; Ahmed, A. Sayed; More

HemaSphere. 3(S1):1075, June 2019.

Author:
Abdeljelil, N.
Author:
abdellatif, H.
Author:
Abdelmeguid, Y.
Author:
Abdelrahim, M.

PB1737 MULTICENTER, RANDOMIZED, CROSSOVER STUDY TO EVALUATE THE BIOEQUIVALENCE AND FOOD EFFECT ON THE BIOAVAILABILITY OF CC-486 (ORAL AZACITIDINE) TABLETS IN ADULT CANCER PATIENTS

Babiker, H.; Milhem, M.; Aisner, J.; More

HemaSphere. 3(S1):799, June 2019.

Author:
Abdelrahman, H.
Author:
Abdelraouf, R.
Author:
Abdelrazik, A.
Author:
Abdelwahab, M.
Author:
Abdulalimov, E.
Author:
Abdulla, H.
Author:
Abdullaev, A.
Author:
Abdulrahman, S.
Author:
Abe, Y.
Author:
Abedi, M.

PS1500 HEALTHCARE RESOURCE UTILIZATION (HCRU) IN PATIENTS (PTS) WITH NEWLY DIAGNOSED (ND) ACUTE MYELOID LEUKEMIA (AML) TREATED IN THE CONNECT® MDS/AML DISEASE REGISTRY

Mukherjee, S.; Abedi, M.; Erba, H.P.; More

HemaSphere. 3(S1):691, June 2019.

Author:
Abella, E.

PS1391 ASSESSMENT OF THE BURDEN OF DISEASE IN TERMS OF HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH MULTIPLE MYELOMA NOT ELIGIBLE FOR ASCT IN SPAIN: INTERIM ANALYSIS OF QOLMMBUS STUDY

de la Rubia, J.; Domingo, A.; Delgado, O.; More

HemaSphere. 3(S1):638, June 2019.

PB2009 PERIPHERAL BLOOD INVOLVEMENT BY FLOW CYTOMETRY IS NOT AN UNUSUAL FEATURE IN IGM MGUS/WALDENSTRÖM MACROGLOBULINEMIA WITH MYD88 L265P MUTATION.

Montesdeoca, S.; Calvo, X.; Arenillas, L.; More

HemaSphere. 3(S1):908-909, June 2019.

PB2144 PRESCRIPTION PATTERNS AND OUTCOMES OF FIRST-LINE THERAPY FOR NON-TRANSPLANT ELIGIBLE MULTIPLE MYELOMA REAL-LIFE PATIENTS ACCORDING TO AGE: A RETROSPECTIVE ANALYSIS OF THE 2012-2016 PERIOD

Cejalvo, M. J.; Sureda, A.; González, E.; More

HemaSphere. 3(S1):964-965, June 2019.

Author:
Abello, V.

PB2124 OVERALL SURVIVAL OF MULTIPLE MYELOMA (MM) PATIENTS IN COLOMBIA: REPORT OF THE COLOMBIAN REGISTRY FOR HEMATO-ONCOLOGICAL DISEASES (RENEHOC) ASOCIACIÓN COLOMBIANA DE HEMATOLOGÍA Y ONCOLOGÍA (ACHO)

Melo, C. Sossa; Abello, V.; Idrobo, H.; More

HemaSphere. 3(S1):956-957, June 2019.

Author:
Abeykoon, J.

PF485 PARTIAL RESPONSE OR BETTER AT 6 MONTHS IS PROGNOSTIC OF PROGRESSION-FREE SURVIVAL IN PATIENTS WITH WALDENSTROM MACROGLOBULINEMIA TREATED WITH IBRUTINIB

Castillo, J.; Abeykoon, J.; Gustine, J.; More

HemaSphere. 3(S1):194-195, June 2019.

Author:
Abeysuriya, V.
Author:
Abhyankar, S.

PS1056 ACUTE MYELOID LEUKEMIA OR MYELODYSPLASTIC SYNDROME WITH CHROMOSOME 17 ABNORMALITIES AND LONG-TERM OUTCOMES WITH OR WITHOUT HEMATOPOIETIC STEM CELL TRANSPLANTATION

Mohyuddin, G.R.; Britt, A.; Skikne, B.; More

HemaSphere. 3(S1):477-478, June 2019.

PB2335 COMPARISON BETWEEN FOUR AND FIVE DAYS OF G-CSF-INDUCED MOBILIZATION IN ALLOGENEIC STEM CELL DONORS

Moro, F. Martin; Prieto, C. Jiménez; García, I. García; More

HemaSphere. 3(S1):1040-1041, June 2019.

PB2381 INFLUENCE OF THE DONOR ON THE RESULTS OF THE ALLOGENIC STEM CELL TRANSPLANT IN PATIENTS WITH ACUTE MYELOID LEUKEMIA. ROLE OF HAPLOIDENTICAL DONOR

García, I. García; Rodríguez, A. Chinea; Moro, F. Martín; More

HemaSphere. 3(S1):1059, June 2019.

Author:
Abidin, N.Z.

S889 GRANULOCYTES AND MONO-NUCLEAR CELLS FROM PATIENTS WITH MYELOPROLIFERATIVE DISORDERS HARBOUR PERSISTENT EVIDENCE OF DNA DAMAGE AND TP53 PATHWAY ACTIVATION THAT CORRELATES WITH JAK-STAT ACTIVATION

Innes, A.; Robinson, M.; Gerrard, G.; More

HemaSphere. 3(S1):400, June 2019.

Author:
Abildgaard, N.

PF626 HEALTH-RELATED QUALITY OF LIFE (HRQOL) OUTCOMES OF ORAL IXAZOMIB MAINTENANCE THERAPY POST AUTOLOGOUS STEM CELL TRANSPLANT (ASCT) IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) FROM TOURMALINE-MM3

Schjesvold, F.; Goldschmidt, H.; Maisnar, V.; More

HemaSphere. 3(S1):266-267, June 2019.

PS1418 POMALIDOMIDE-BASED TREATMENT IN RELAPSED REFRACTORY MULTIPLE MYELOMA: ANALYSIS OF BASELINE CHARACTERISTICS AND SAFETY PROFILE OF PATIENTS WHO DIED IN THE EUROPEAN POST APPROVAL SAFETY STUDY

Gamberi, B.; Abildgaard, N.; Payer, A. Ramirez; More

HemaSphere. 3(S1):652, June 2019.

S1602 CARFILZOMIB AND DEXAMETHASONE MAINTENANCE PROLONG TIME TO PROGRESSION: FOLLOWING SALVAGE ASCT IN MULTIPLE MYELOMA: A RANDOMIZED PHASE 2 TRIAL BY THE NORDIC MYELOMA STUDY GROUP

Gregersen, H.; Peceliunas, V.; Remes, K.; More

HemaSphere. 3(S1):737-738, June 2019.

Author:
Abiodun, M.
Author:
Abonour, R.

PF601 EVOLVING TREATMENT PATTERNS IN MULTIPLE MYELOMA (MM) DIFFER BY AGE AND REGION: ANALYSIS FROM INSIGHT MM, A GLOBAL, PROSPECTIVE, OBSERVATIONAL STUDY

Chari, A.; Weisel, K.C.; Usmani, S.Z.; More

HemaSphere. 3(S1):254, June 2019.